JP4448034B2 - 淫羊霍抽出物の薬物調製上における応用 - Google Patents
淫羊霍抽出物の薬物調製上における応用 Download PDFInfo
- Publication number
- JP4448034B2 JP4448034B2 JP2004559564A JP2004559564A JP4448034B2 JP 4448034 B2 JP4448034 B2 JP 4448034B2 JP 2004559564 A JP2004559564 A JP 2004559564A JP 2004559564 A JP2004559564 A JP 2004559564A JP 4448034 B2 JP4448034 B2 JP 4448034B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- polysaccharide
- flavonoids
- content
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000284 extract Substances 0.000 title claims abstract description 84
- 239000003814 drug Substances 0.000 title claims description 22
- 229940079593 drug Drugs 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title description 15
- 150000004676 glycans Chemical class 0.000 claims abstract description 68
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 64
- 239000005017 polysaccharide Substances 0.000 claims abstract description 64
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract description 31
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 201000007094 prostatitis Diseases 0.000 claims abstract description 16
- 241000208340 Araliaceae Species 0.000 claims abstract description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 4
- 235000008434 ginseng Nutrition 0.000 claims abstract description 4
- 210000002307 prostate Anatomy 0.000 claims abstract description 3
- 238000009472 formulation Methods 0.000 claims abstract 3
- 239000009636 Huang Qi Substances 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- 229930003935 flavonoid Natural products 0.000 claims description 58
- 150000002215 flavonoids Chemical class 0.000 claims description 58
- 235000017173 flavonoids Nutrition 0.000 claims description 58
- 235000019441 ethanol Nutrition 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 240000008564 Boehmeria nivea Species 0.000 claims description 15
- 229940000425 combination drug Drugs 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 206010023126 Jaundice Diseases 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 13
- 229910052609 olivine Inorganic materials 0.000 claims description 12
- 239000010450 olivine Substances 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 229930182470 glycoside Natural products 0.000 claims description 9
- 150000002338 glycosides Chemical class 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 244000000626 Daucus carota Species 0.000 claims description 8
- 235000002767 Daucus carota Nutrition 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- IYCPMVXIUPYNHI-UHFFFAOYSA-N Icariside I Natural products C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 IYCPMVXIUPYNHI-UHFFFAOYSA-N 0.000 claims description 7
- 229930182478 glucoside Natural products 0.000 claims description 7
- 150000008131 glucosides Chemical class 0.000 claims description 7
- 150000007949 saponins Chemical class 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 6
- 229930182490 saponin Natural products 0.000 claims description 6
- 229930013930 alkaloid Natural products 0.000 claims description 5
- 229940008396 carrot extract Drugs 0.000 claims description 5
- 235000020710 ginseng extract Nutrition 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 4
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 4
- 229940093265 berberine Drugs 0.000 claims description 4
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 206010020880 Hypertrophy Diseases 0.000 claims description 3
- RGDJCYRXKJVXKD-UHFFFAOYSA-N Saponin 3 Natural products COC(=O)C1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(C)(C)C5CCC34C)C2C1)C(=O)O RGDJCYRXKJVXKD-UHFFFAOYSA-N 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- IYCPMVXIUPYNHI-WPKKLUCLSA-N 3,5-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 IYCPMVXIUPYNHI-WPKKLUCLSA-N 0.000 claims description 2
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 claims description 2
- 241000255777 Lepidoptera Species 0.000 claims description 2
- 229930002875 chlorophyll Natural products 0.000 claims description 2
- 235000019804 chlorophyll Nutrition 0.000 claims description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241000920652 Quercus lusitanica Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 241000893536 Epimedium Species 0.000 abstract description 3
- 235000018905 epimedium Nutrition 0.000 abstract description 3
- 229930003944 flavone Natural products 0.000 abstract 3
- 150000002213 flavones Chemical class 0.000 abstract 3
- 235000011949 flavones Nutrition 0.000 abstract 3
- 206010067482 No adverse event Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 description 17
- 230000007423 decrease Effects 0.000 description 15
- 201000004240 prostatic hypertrophy Diseases 0.000 description 13
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 11
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 11
- 208000013507 chronic prostatitis Diseases 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 230000002485 urinary effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 6
- 235000019687 Lamb Nutrition 0.000 description 5
- 208000032023 Signs and Symptoms Diseases 0.000 description 5
- 206010046555 Urinary retention Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 150000004804 polysaccharides Polymers 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 241000219122 Cucurbita Species 0.000 description 3
- 235000009852 Cucurbita pepo Nutrition 0.000 description 3
- 241000893531 Epimedium koreanum Species 0.000 description 3
- 241001660849 Epimedium pubescens Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 206010036596 premature ejaculation Diseases 0.000 description 3
- 238000009666 routine test Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001362421 Epimedium brevicornu Species 0.000 description 2
- 241001362411 Epimedium sagittatum Species 0.000 description 2
- 241001362415 Epimedium wushanense Species 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 241000283903 Ovis aries Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 241001016310 Epimedium grandiflorum Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000209490 Nymphaea Species 0.000 description 1
- 241000819999 Nymphes Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
各種淫羊霍植物のフラボノイド及び多糖類含有量の測定淫羊霍抽出物の調製に使用する植物には,淫羊霍(Epimedium brevicornum),箭葉淫羊霍(E. sagittatum),柔毛淫羊霍(E. pubescens),烏山淫羊霍(E. wushanense),及び朝鮮淫羊霍(E. koreanum)があり,地上部の茎葉を用いる。それぞれ,四川,陝西,湖南,湖北,貴州,遼寧等の省にて採集される。総フラボノイドの測定にはUV法,淫羊霍配糖体(icarrin)と淫羊霍配糖体I(icarisid I)の測定にはHPLC法,多糖類含有量測定にはフェノール硫酸法を用いる。測定結果により,総フラボノイドの含有量は6〜20%,総多糖類の含有量は13〜26%であることが示された。
淫羊霍(陝西にて採集の葉を粗くきざんだ粉末500gを,60%エチルアルコール溶液3リットルを用い,60℃で2時間かけ,3回に分けて抽出する。抽出液を濾過して全部合わせ,減圧し有機溶剤を回収し,水溶液を多孔性吸着樹脂カラム(D101或いはD140,湿潤重量1000g)に吸着させる。まず3リットルの水で洗浄し,再度30〜85%エチルアルコール溶液にて洗浄し,エチルアルコール洗浄液を減圧回収し,乾燥させた後,A部分20gを採取する(採取率3%,フラボノイド含有量45.8%,主要成分は淫羊霍配糖体イカリインと淫羊霍配糖体イカリシドI)。濾過後の残留薬液を3リットルの水で50分間煎じ,3回に分けて抽出を行い,抽出液を濾過し全部あわせ,1リットルになるまで濃縮する。再度濾過し,95%のエチルアルコールを加え,液全体のアルコール濃度を75%にして攪拌し,12時間静置後,濾過し,沈殿物を採取する。水溶アルコール沈殿法による精製を2回繰り返し,赤褐色の多糖類粗製物(56g)を採取する。この多糖類粗製物を500mlの水に溶かし,クロロフォルムとブチルアルコールを5対1の割合で混合した有機溶剤100mlを加え,よく振り混ぜ蛋白質を取り除く。この水溶液を分子量1000の限外濾過膜を用い,分子量1000以下の成分を除き去り,濃縮乾燥させた後,精製淫羊霍多糖類部分B(36.5g)を採取する。この採取物中の多糖類の分子量は1000〜700000である。EPS−1及びEPS−2の2つの多糖類成分が鑑定され,各分子量はそれぞれ45000,及び620000である。多糖類はフコース,ラムノース,アラビノース,キシロース,マンノース,ブドウ糖,ガラクトースの7つの単糖類により組成され,本発明はそれ以外にも4つの多糖類成分を鑑定しており,各分子量はそれぞれ3400,25000,45000,520000である。
この複方は以下の5種類の成分を組み合わせて行う。
淫羊霍抽出物
実験用動物として,SDマウス(昆明種)40匹を使用。体重20±2g,雄雌各半分,実験前に16時間の絶食を行い,飲水は自由にさせる。均等に2組に分け(n=20),第1グループに一回のみ,淫羊霍抽出物I(A対Bの混合比率は4対6。混合後のフラボノイド含有量40%,淫羊霍配糖体10%,多糖類60%)を6g/kg投与する。第2グループに一回のみ,淫羊霍抽出物Iを9g/kg投与する。投与後7日間の観察中に,マウスの食欲,自発活動,糞便,生長発育,及び死亡状況の記録を行う。また,同様の実験操作法と投薬量により,淫羊霍II(A対Bの混合比率は6対4。混合後のフラボノイド含有量40%,淫羊霍配糖体20%,多糖類40%),淫羊霍III,(A対Bの混合比率は7対3。混合後のフラボノイド含有量60%,淫羊霍配糖体60%,多糖類30%)及び実施形態3の淫羊霍複方(淫羊霍,人参,オウギ,花粉,黄柏)のマウスに対する急性毒性観察実験を行う。
1,臨床実験研究の目的
1)淫羊霍抽出物の良性前立腺肥大症に対する適切な治療効果,及び毒性,副作用反応の
観察。
2)前述の実施形態3の淫羊霍複方(淫羊霍,人参,オウギ,花粉,黄柏)の前立腺肥大
と慢性前立腺炎の合併症に対する治療効果,及び毒性,副作用反応の観察。
1)単純性前立腺肥大症に符合する年齢50歳以上の患者。
2)前立腺炎を伴う前立腺肥大症がある年齢30歳以上の患者。
3)症状,及び徴候の積分≧6分がみられ,また理化学的検査により相応の異常が確認された患者。
4)インポテンツ,早漏を伴う前立腺肥大症患者。
良性前立腺肥大グループ:淫羊霍抽出物(A対Bの混合比率は6対4。混合後のフラボノイド含有量40%,淫羊霍配糖体20%,多糖類40%)を使用。薬剤量は250mg/粒´3粒´2回/日。
血液常用検査:治療前後のRBC,Hb,WBC,Pltの変化を観察する。
資料の計量にはX±SD表示,2標本のデータ比較にt−test,群間比較にはRidit分析を使用。
Claims (10)
- 重量比2〜8割の総フラボノイドと8〜2割の多糖類を含み,総フラボノイド中のフラボノイドの含量は20〜90%,多糖類の分子量範囲は1000〜700000であることを特徴とする,淫羊霍属植物の抽出物を含有する前立腺肥大症治療用配合薬物。
- 淫羊霍総フラボノイドと多糖類の成分比率は3〜6割対7〜4割であり,総フラボノイド中における淫羊霍配糖体イカリイン及び淫羊霍配糖体イカリシドIの含有量は10〜90%,多糖類の分子量範囲は45000〜62000であることを特徴とする請求項1に記載の配合薬物。
- 淫羊霍薬材を60〜95%有機溶剤水溶液を用いて抽出し,抽出液中の有機溶剤を減圧回収した後の残留物を多孔性吸着樹脂カラム(D101或いはD140)に吸着させ,水とエチルアルコールによるグラジェント溶出法を用いて洗浄し,30〜85%濃度のエチルアルコール液部分を収集し,減圧回収,乾燥後,総フラボノイド中のフラボノイド含有量が20〜90重量%である総フラボノイドを採取し,60〜95%有機溶剤水溶液にて淫羊霍を抽出した残留薬液を,水を用いて再度抽出し,抽出液を濃縮し,液全体のアルコール濃度が70〜85%になるようエチルアルコールを加え,静置後,濾過し,多糖類粗製物を採取し,この多糖類粗製物を水に溶かし,体積比3〜6割のクロロフィルと1割のブチルアルコールの混合液を加え,たんぱく質を取り除き,分子量1000の限外濾過膜を用いて濾過し,分子量1000以下の成分を除去し,濃縮液をさらに濃縮し乾燥させた後,分子量範囲1000〜700000の淫羊霍多糖類を採取し,重量比にして2〜8割の淫羊霍総フラボノイドと,8〜2割の多糖類を混合することにより調整された,請求項1または2に記載の配合薬物。
- 淫羊霍の抽出において使用される60〜95%有機溶剤水溶液は,アセトン,プロピルアルコール,イソプロピルアルコール或いはメチルアルコールから成り,淫羊霍フラボノイドと多糖類の組成比率は3〜6割対7〜4割であることを特徴とする,請求項3に記載の配合薬物。
- 淫羊霍抽出物の総フラボノイド中の淫羊霍配糖体(icarrin)と,配糖体I(icarisid I)の含有量は10〜90%であり,多糖類粗製物は,再び水に溶かし,液全体のアルコール濃度が70〜85%になるようにエチルアルコールを加え,静置,濾過した後,分子量45000〜620000の多糖類抽出物を採取することを特徴とする,請求項4に記載の配合薬物。
- 淫羊霍総フラボノイドと多糖類の成分比率は3対8,4対6,5対5,6対4,7対3のいずれかであり,薬学上,担体との組み合わせ,またはその他の補助薬材との混合が可能であることを特徴とする,請求項5に記載の配合薬物。
- 人参,花粉,オウギ,黄柏,淫羊霍フラボノイド,及び淫羊霍多糖類を含むか,あるいは,淫羊霍属植物の抽出物を単独で含み,淫羊霍属植物の抽出物中に重量比2〜8割の総フラボノイドと8〜2割の多糖類を含み,総フラボノイド中のフラボノイドの含量は20〜90%,多糖類の分子量範囲は1000〜700000であることを特徴とする前立腺肥大症または前立腺炎治療用配合薬物。
- 重量比にして,人参抽出物(ニンジンサポニン含有量6〜10%)を1〜6割,花粉また花粉抽出物(フラボノイド含有量10〜20%)を1〜8割,オウギ抽出物(オウギcサポニン3〜5%,及びオウギ多糖類20〜30%)を1〜4割,黄柏抽出物(アルカロイドベルベリン10〜15%)を1〜6割,淫羊霍総フラボノイド(フラボノイド含有量20〜90%),または淫羊霍多糖類を4〜16割含有することを特徴とする,請求項7に記載の配合薬物。
- 人参抽出物1〜2割,花粉或いは花粉抽出物2〜4割,オウギ抽出物1〜2割,黄柏抽出物1〜2割,淫羊霍フラボノイド或いは淫羊霍多糖類5〜10割を含むことを特徴とする,請求項8に記載の配合薬物。
- 薬学上の担体との組み合わせ,または補助薬材との混合により,各種内服製剤として構成されることを特徴とする,請求項7〜9のいずれかに記載の配合薬物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021485712A CN1194702C (zh) | 2002-12-18 | 2002-12-18 | 治疗前列腺肥大的淫羊藿提取物及其在制备药物中的应用 |
PCT/CN2003/000994 WO2004054596A1 (fr) | 2002-12-18 | 2003-11-24 | Medicament contenant un extrait d'epimedium et destine au traitement de l'hyperplasie prostatique et de la prostatite |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006510678A JP2006510678A (ja) | 2006-03-30 |
JP4448034B2 true JP4448034B2 (ja) | 2010-04-07 |
Family
ID=4751485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004559564A Expired - Lifetime JP4448034B2 (ja) | 2002-12-18 | 2003-11-24 | 淫羊霍抽出物の薬物調製上における応用 |
Country Status (9)
Country | Link |
---|---|
US (2) | US7205005B2 (ja) |
EP (1) | EP1574218B1 (ja) |
JP (1) | JP4448034B2 (ja) |
KR (1) | KR100713088B1 (ja) |
CN (1) | CN1194702C (ja) |
AT (1) | ATE475455T1 (ja) |
AU (1) | AU2003289644A1 (ja) |
DE (1) | DE60333586D1 (ja) |
WO (1) | WO2004054596A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1295224C (zh) * | 2004-11-11 | 2007-01-17 | 中国药科大学 | 注射用淫羊藿总黄酮苷的制备方法 |
KR100803577B1 (ko) * | 2005-11-30 | 2008-02-15 | (주)아모레퍼시픽 | 이카린의 가수분해물을 함유하는 화장료용 조성물 |
EP1952816A1 (en) * | 2007-01-26 | 2008-08-06 | The Jordanian Pharmaceutical Manufacturing Co. | Multi-component herbal composition for the treatment of male erectile dysfunction |
KR101040477B1 (ko) | 2008-06-03 | 2011-06-09 | 고려대학교 산학협력단 | 항안드로겐 조성물 |
KR101144991B1 (ko) * | 2009-12-29 | 2012-06-27 | 대한민국 | 인삼 추출물을 포함하는 전립선비대증을 예방 또는 치료하기 위한 약학적 조성물 및 건강 기능성식품 조성물 |
CN103613675B (zh) * | 2010-11-05 | 2016-08-17 | 北京中安佐际生物科技有限公司 | 淫羊藿多糖及其组分和它们用于疫苗佐剂的用途 |
JP6034293B2 (ja) * | 2010-11-05 | 2016-11-30 | ベイジン チョンアン アジュバント バイオテクノロジー カンパニー,リミティド | イカリソウの多糖、その画分、及びワクチンアジュバントとしてのその使用 |
TWI492754B (zh) | 2012-06-27 | 2015-07-21 | Jin Xin Biotechnology Co Ltd | 台灣山蘇萃取物之用途 |
CA2912438A1 (en) * | 2013-04-10 | 2014-10-16 | Glycobiosciences, Inc. | Topical nutraceutical composition |
CN103565993B (zh) * | 2013-11-11 | 2014-12-10 | 王纯治 | 一种治疗前列腺炎的中药方剂 |
KR20210054481A (ko) | 2019-11-05 | 2021-05-13 | 경희대학교 산학협력단 | 금은화 추출물을 포함하는 전립선비대증 예방 또는 치료용 조성물 |
CN111920858B (zh) * | 2020-09-02 | 2021-10-15 | 毛蕴衡 | 一种组合物及其在制备辅助治疗前列腺炎药物中的应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3116695C2 (de) * | 1980-04-30 | 1985-03-07 | Zenyaku Kogyo K.K., Tokio/Tokyo | Neuer Pflanzenextrakt, Verfahren zu seiner Herstellung und ein ihn enthaltendes Arzneimittel |
CN1093600A (zh) | 1993-04-10 | 1994-10-19 | 河南省三门峡市九九三神力保健品厂 | 前列腺保健品及其制造方法 |
US5587167A (en) * | 1993-09-14 | 1996-12-24 | Choi; Hyung K. | Pharmaceutical composition for prophylaxis and treatment of premature ejaculation |
CN1113802A (zh) * | 1994-05-27 | 1995-12-27 | 四川省遂宁市医药研究所 | 前列宁冲剂 |
CA2137219C (en) * | 1994-12-02 | 1997-10-21 | Salva Gideon | Extract for improving male sperm count and use as anti-microbial or anti-inflammatory agent |
CN1219408A (zh) * | 1997-12-07 | 1999-06-16 | 孙树春 | 安神通神胶囊 |
CN1058902C (zh) | 1998-02-25 | 2000-11-29 | 荆延有 | 壮肾助阳液 |
US6123944A (en) * | 1998-03-19 | 2000-09-26 | Phytoceutica, Inc. | Icariin preparations |
CN1245194C (zh) * | 2000-04-28 | 2006-03-15 | 韩富生 | 治疗老年性前列腺肥大的口服液 |
US6750248B2 (en) * | 2001-11-09 | 2004-06-15 | National University Of Singapore | Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
US6476203B1 (en) * | 2002-03-14 | 2002-11-05 | Xinxian Zhao | Safe pharmaceutical composition for treating and preventing infertility and increasing immune function |
-
2002
- 2002-12-18 CN CNB021485712A patent/CN1194702C/zh not_active Expired - Lifetime
-
2003
- 2003-11-24 WO PCT/CN2003/000994 patent/WO2004054596A1/zh active Application Filing
- 2003-11-24 AU AU2003289644A patent/AU2003289644A1/en not_active Abandoned
- 2003-11-24 DE DE60333586T patent/DE60333586D1/de not_active Expired - Lifetime
- 2003-11-24 AT AT03779644T patent/ATE475455T1/de not_active IP Right Cessation
- 2003-11-24 EP EP03779644A patent/EP1574218B1/en not_active Expired - Lifetime
- 2003-11-24 KR KR1020057011420A patent/KR100713088B1/ko active IP Right Grant
- 2003-11-24 JP JP2004559564A patent/JP4448034B2/ja not_active Expired - Lifetime
- 2003-11-24 US US10/539,497 patent/US7205005B2/en not_active Expired - Lifetime
-
2006
- 2006-06-28 US US11/476,458 patent/US7250182B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE60333586D1 (de) | 2010-09-09 |
KR20050084420A (ko) | 2005-08-26 |
EP1574218A4 (en) | 2007-06-06 |
US7205005B2 (en) | 2007-04-17 |
EP1574218A1 (en) | 2005-09-14 |
US20060105067A1 (en) | 2006-05-18 |
ATE475455T1 (de) | 2010-08-15 |
JP2006510678A (ja) | 2006-03-30 |
CN1194702C (zh) | 2005-03-30 |
KR100713088B1 (ko) | 2007-05-02 |
CN1422622A (zh) | 2003-06-11 |
US7250182B2 (en) | 2007-07-31 |
US20060246164A1 (en) | 2006-11-02 |
AU2003289644A1 (en) | 2004-07-09 |
WO2004054596A1 (fr) | 2004-07-01 |
EP1574218B1 (en) | 2010-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Singhuber et al. | Aconitum in traditional Chinese medicine—a valuable drug or an unpredictable risk? | |
CN101167749B (zh) | 一种改善蟾酥口味的炮制方法 | |
JP4448034B2 (ja) | 淫羊霍抽出物の薬物調製上における応用 | |
CN102698137B (zh) | 一种具有降低血压作用的组合物及其制备方法 | |
CN104013668B (zh) | 甘草黄酮类提取物用于制备治疗溃疡性结肠炎药物中应用 | |
WO2004052383A1 (fr) | Composition contenant des saponines triterpenoides extraites de bambou, son procede de preparation et son utilisation | |
CN101161251B (zh) | 续断总皂苷提取物及其提取方法和应用 | |
JP2006510592A (ja) | スイカズラ(LonicerajaponicaThunb.)茎の活性成分の抽出および精製方法、その消炎鎮痛剤への用途 | |
US8945633B2 (en) | Pharmaceutical composition for preventing and treating inflammatory diseases containing an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient, and method for producing the fraction | |
Cimanga et al. | The spasmolytic activity of extracts and some isolated compounds from the leaves of Morinda morindoides (Baker) Milne-Redh.(Rubiaceae) | |
CN102512482A (zh) | 一种鬼箭羽提取物及其降糖活性与在制备降血糖制品中的应用 | |
CN101829261B (zh) | 一种治疗银屑病的中药及其制备方法和检测方法 | |
CN101185661A (zh) | 地钱提取物的制备工艺及其在制备治疗肝癌和乙型肝炎药物中的应用 | |
KR0160108B1 (ko) | 조각자나무로부터 추출한 생약 성분으로 된 항암제 | |
CN115025112B (zh) | 白芷多糖在制备防治溃疡性结肠炎的药物中的用途 | |
CN101411779B (zh) | 一种治疗肝癌的中药有效部位组合物及其制备方法 | |
CN100335073C (zh) | 木鳖子含三萜皂甙成分提取物的制备方法 | |
WO2011016652A2 (ko) | 항치루 조성물 및 그 제조 방법 | |
CN1241618C (zh) | 丫蕊花(Ypsilandra)属植物在制备治疗出血性疾病药物中的应用 | |
CN101721450B (zh) | 一种用于治疗腹膜炎的苍耳根氯仿提取物的应用 | |
CN1254260C (zh) | 含淫羊藿提取物的药物组合物 | |
CN1839867A (zh) | 具有清热、泻火和解毒作用的药物组合物 | |
CN114767695B (zh) | 水葱内酯的提取方法及其应用 | |
CN116509921B (zh) | 米团花二倍半萜提取物k01在制备治疗脓毒血症的药物中的应用 | |
CN101411778A (zh) | 一种中药有效部位组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090728 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091201 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100105 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100121 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130129 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4448034 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160129 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |